These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 20211816)
1. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. Assimon MM; Mousa S; Shaker O; Pai AB Consult Pharm; 2010 Jan; 25(1):41-54. PubMed ID: 20211816 [TBL] [Abstract][Full Text] [Related]
2. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. St Peter WL; Liu J; Weinhandl E; Fan Q Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis. Prajapati VA; Galani VJ; Shah PR Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. St Peter WL; Fan Q; Weinhandl E; Liu J Clin J Am Soc Nephrol; 2009 Dec; 4(12):1954-61. PubMed ID: 19833904 [TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157 [TBL] [Abstract][Full Text] [Related]
6. Oral phosphate binders for the management of serum phosphate levels in dialysis patients. Mohammed I; Hutchison AJ J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Mason MA; Shepler BM Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637 [TBL] [Abstract][Full Text] [Related]
8. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related]
9. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Suki WN; Zabaneh R; Cangiano JL; Reed J; Fischer D; Garrett L; Ling BN; Chasan-Taber S; Dillon MA; Blair AT; Burke SK Kidney Int; 2007 Nov; 72(9):1130-7. PubMed ID: 17728707 [TBL] [Abstract][Full Text] [Related]
10. Ten-year experience with sevelamer and calcium salts as phosphate binders. Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501 [TBL] [Abstract][Full Text] [Related]
11. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Nolan CR; Qunibi WY Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333 [TBL] [Abstract][Full Text] [Related]
12. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL Drugs; 2008; 68(1):85-104. PubMed ID: 18081374 [TBL] [Abstract][Full Text] [Related]
13. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T; Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280 [TBL] [Abstract][Full Text] [Related]
15. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D. Yusuf AA; Weinhandl ED; St Peter WL Am J Kidney Dis; 2014 Jul; 64(1):95-103. PubMed ID: 24387795 [TBL] [Abstract][Full Text] [Related]
17. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Suki WN; J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452 [TBL] [Abstract][Full Text] [Related]
18. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307 [TBL] [Abstract][Full Text] [Related]
19. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Patel L; Bernard LM; Elder GJ Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024 [TBL] [Abstract][Full Text] [Related]
20. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice. Winkelmayer WC; Tonelli M Am J Kidney Dis; 2008 Mar; 51(3):362-5. PubMed ID: 18295050 [No Abstract] [Full Text] [Related] [Next] [New Search]